The evolving medication landscape underscores the importance of individualized treatment planning, integrating both pharmacological and behavioral interventions to support long-term recovery across substance categories
2015048003) at Seoul National University in Korea
The majority of the published literature examines each compound independently, and the synergy hypothesis, while mechanistically well-supported, has not yet been the subject of large-scale controlled studies
[This excludes those items that are used to replace skin.] Thus, because the Axoguard HA+ Nerve Protector TM is an ECM obtained from porcine SIS and intended to support a damaged or inadequate soft tissue (nerve), we stated that we believe that the pass-through payment category C1763 may appropriately describe the Axoguard HA+ Nerve Protector TM
The study was conducted in accordance with the local legislation and institutional requirements
Published studies have demonstrated effects including increased callus formation at fracture sites, enhanced osteoblast differentiation and activity, improved bone mineral density at healing sites, and acceleration of the transition from woven bone to lamellar bone
